Drug Profile


Alternative Names: BMY 13105; Bucindolol hydrochloride; Gencaro; MJ 13105; MJ 131051

Latest Information Update: 10 Dec 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ARCA biopharma Inc
  • Class Heart failure therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Atrial fibrillation; Heart failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Atrial fibrillation
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 06 Oct 2016 Phase-II/III clinical trials in Atrial fibrillation (Prevention) in Hungary (PO) (NCT01970501)
  • 13 Jul 2016 Phase-II/III clinical trials in Atrial fibrillation (Prevention) in Poland (PO) (EudraCT2016-000302-12)
  • 16 Dec 2015 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top